Suppliers / Solara Active Pharma Sciences

Solara Active Pharma Sciences

India SOLARAPP1.BO Updated 9 July 2026

Solara Active Pharma Sciences is an API manufacturer based in India. It holds 91 active US drug master files and 32 valid CEPs. Its GMP standing is certified by CDSCO (India), US FDA and EMA, among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 6 February 2026 as VAI. Customs aggregates show $85.7M of exports covering 1,240 molecules to 62 destinations in 2025.

91
active US DMFs
32
valid CEPs
12
registered plants 6 with an FDA FEI number
2
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
6 of 6 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 6 February 2026 VAI US FDA
  • 29 August 2025 VAI US FDA
  • 9 May 2025 NAI US FDA
  • 17 May 2024 NAI US FDA
  • 4 August 2023 NAI US FDA
  • 7 March 2020 OAI US FDA
  • 21 February 2020 NAI US FDA
  • 21 February 2020 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Chennai, India Not on file
Mysuru, India 3011856449
Anakapalli District, India 3016965485
New Mangalore, India 3008252997
Periyakalapet, India 3002808058
Pondicherry, India Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Ibuprofen EDQM, SFDA (Saudi Arabia), US FDA 9
Mefenamic Acid EDQM, US FDA 4
Colchicine EDQM, SFDA (Saudi Arabia), US FDA 3
Dextromethorphan EDQM, US FDA 3
Hydralazine EDQM, SFDA (Saudi Arabia), US FDA 3
Levetiracetam EDQM, SFDA (Saudi Arabia), US FDA 3
Mycophenolic Acid EDQM, US FDA 3
Succinylcholine EDQM, SFDA (Saudi Arabia), US FDA 3
Aprepitant EDQM, US FDA 2
Bumetanide EDQM, US FDA 2
Show all 30 molecules on file
Buspirone EDQM, US FDA 2
Celecoxib EDQM, US FDA 2
Dipyridamole EDQM, US FDA 2
Disulfiram EDQM, US FDA 2
Etomidate EDQM, US FDA 2
Flecainide EDQM, US FDA 2
Gabapentin EDQM, US FDA 2
Mesalazine EDQM, US FDA 2
Mesna EDQM, US FDA 2
Mirabegron EDQM, US FDA 2
Mycophenolate Mofetil EDQM, SFDA (Saudi Arabia) 2
Naproxen US FDA 2
Nizatidine EDQM, US FDA 2
Olanzapine EDQM, US FDA 2
Oseltamivir EDQM, US FDA 2
Praziquantel EDQM, US FDA 2
Sevelamer US FDA 2
Venlafaxine EDQM, US FDA 2
Acitretin US FDA 1
Acyclovir US FDA 1

Also appears on these molecule pages

Show 20 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 2 5
US FDA None 5
EMA None 3
MFDS (Korea) None 2

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $13.8M 40
2025 Not reported $85.7M 62
2024 Not reported $95.4M 63
2023 Not reported $95.8M 63

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Solara Active Pharma Sciences comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 1 active litigation matter is on record.
  • The most recent inspection outcome was VAI, on 6 February 2026.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts